Health Canada gives thumbs up to Xience V

Justine Varieur Cadet | | Health Imaging | Diagnostic Imaging
Abbott has received approval from Health Canada for the Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease.

Abbott Park, Ill.-based company said it will launch Xience V in Canada immediately.

Xience V is built upon Abbott's bare-metal stent, the Multi-Link Vision coronary stent system. Abbott said its Vision platform is designed to facilitate ease of delivery to maneuver the stent and treat the diseased portion of the artery. The Xience V drug-coated stent will be available on both over-the-wire and rapid exchange delivery systems.

Justine Varieur Cadet

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.